189 related articles for article (PubMed ID: 34242699)
1. 24-Norursodeoxycholic acid reshapes immunometabolism in CD8
Zhu C; Boucheron N; Müller AC; Májek P; Claudel T; Halilbasic E; Baazim H; Lercher A; Viczenczova C; Hainberger D; Preglej T; Sandner L; Alteneder M; Gülich AF; Khan M; Hamminger P; Remetic J; Ohradanova-Repic A; Schatzlmaier P; Donner C; Fuchs CD; Stojakovic T; Scharnagl H; Sakaguchi S; Weichhart T; Bergthaler A; Stockinger H; Ellmeier W; Trauner M
J Hepatol; 2021 Nov; 75(5):1164-1176. PubMed ID: 34242699
[TBL] [Abstract][Full Text] [Related]
2. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
3. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
Halilbasic E; Fiorotto R; Fickert P; Marschall HU; Moustafa T; Spirli C; Fuchsbichler A; Gumhold J; Silbert D; Zatloukal K; Langner C; Maitra U; Denk H; Hofmann AF; Strazzabosco M; Trauner M
Hepatology; 2009 Jun; 49(6):1972-81. PubMed ID: 19475687
[TBL] [Abstract][Full Text] [Related]
4. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
Sombetzki M; Fuchs CD; Fickert P; Österreicher CH; Mueller M; Claudel T; Loebermann M; Engelmann R; Langner C; Sahin E; Schwinge D; Guenther ND; Schramm C; Mueller-Hilke B; Reisinger EC; Trauner M
J Hepatol; 2015 Apr; 62(4):871-8. PubMed ID: 25463533
[TBL] [Abstract][Full Text] [Related]
5. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
[TBL] [Abstract][Full Text] [Related]
7. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
Ravichandran G; Neumann K; Berkhout LK; Weidemann S; Langeneckert AE; Schwinge D; Poch T; Huber S; Schiller B; Hess LU; Ziegler AE; Oldhafer KJ; Barikbin R; Schramm C; Altfeld M; Tiegs G
J Hepatol; 2019 Oct; 71(4):773-782. PubMed ID: 31173810
[TBL] [Abstract][Full Text] [Related]
8. Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
Halilbasic E; Steinacher D; Trauner M
Dig Dis; 2017; 35(3):288-292. PubMed ID: 28249255
[TBL] [Abstract][Full Text] [Related]
9. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
10. Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP.
König J; Klatt S; Dilger K; Fromm MF
Basic Clin Pharmacol Toxicol; 2012 Aug; 111(2):81-6. PubMed ID: 22333292
[TBL] [Abstract][Full Text] [Related]
11. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.
Krones E; Eller K; Pollheimer MJ; Racedo S; Kirsch AH; Frauscher B; Wahlström A; Ståhlman M; Trauner M; Grahammer F; Huber TB; Wagner K; Rosenkranz AR; Marschall HU; Fickert P
J Hepatol; 2017 Jul; 67(1):110-119. PubMed ID: 28242240
[TBL] [Abstract][Full Text] [Related]
12. Macrophages in cholangiopathies.
Bruneau A; Guillot A; Tacke F
Curr Opin Gastroenterol; 2022 Mar; 38(2):114-120. PubMed ID: 35098932
[TBL] [Abstract][Full Text] [Related]
13. Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice.
Wanek T; Halilbasic E; Visentin M; Mairinger S; Römermann K; Stieger B; Kuntner C; Müller M; Langer O; Trauner M
J Pharm Sci; 2016 Jan; 105(1):106-12. PubMed ID: 26852845
[TBL] [Abstract][Full Text] [Related]
14. 24-Norursodeoxycholic acid ameliorates experimental alcohol-related liver disease and activates hepatic PPARγ.
Grander C; Meyer M; Steinacher D; Claudel T; Hausmann B; Pjevac P; Grabherr F; Oberhuber G; Grander M; Brigo N; Jukic A; Schwärzler J; Weiss G; Adolph TE; Trauner M; Tilg H
JHEP Rep; 2023 Nov; 5(11):100872. PubMed ID: 37818230
[TBL] [Abstract][Full Text] [Related]
15. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis.
Beraza N; Ofner-Ziegenfuss L; Ehedego H; Boekschoten M; Bischoff SC; Mueller M; Trauner M; Trautwein C
Gut; 2011 Mar; 60(3):387-96. PubMed ID: 21115542
[TBL] [Abstract][Full Text] [Related]
16. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
Moustafa T; Fickert P; Magnes C; Guelly C; Thueringer A; Frank S; Kratky D; Sattler W; Reicher H; Sinner F; Gumhold J; Silbert D; Fauler G; Höfler G; Lass A; Zechner R; Trauner M
Gastroenterology; 2012 Jan; 142(1):140-151.e12. PubMed ID: 22001865
[TBL] [Abstract][Full Text] [Related]
17. Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
Li J; Zhu X; Zhang M; Zhang Y; Ye S; Leng Y; Yang T; Kong L; Zhang H
J Hepatol; 2021 Aug; 75(2):400-413. PubMed ID: 33746084
[TBL] [Abstract][Full Text] [Related]
18. Autophagy induced by exogenous bile acids is therapeutic in a model of α-1-AT deficiency liver disease.
Tang Y; Fickert P; Trauner M; Marcus N; Blomenkamp K; Teckman J
Am J Physiol Gastrointest Liver Physiol; 2016 Jul; 311(1):G156-65. PubMed ID: 27102560
[TBL] [Abstract][Full Text] [Related]
19. The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver.
Trottier J; El Husseini D; Perreault M; Pâquet S; Caron P; Bourassa S; Verreault M; Inaba TT; Poirier GG; Bélanger A; Guillemette C; Trauner M; Barbier O
J Biol Chem; 2010 Jan; 285(2):1113-21. PubMed ID: 19889628
[TBL] [Abstract][Full Text] [Related]
20. Itaconate inhibits CD103 + T RM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
Li Y; Li B; Xiao X; Qian Q; Wang R; Lyu Z; Chen R; Cui N; Ou Y; Pu X; Miao Q; Wang Q; Lian M; Gershwin ME; Tang R; Ma X; You Z
Hepatology; 2024 Jan; 79(1):25-38. PubMed ID: 37505225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
